MktsMarkets

Royalty Pharma plc
NASDAQ: RPRXKey statistics
RPRX News
Stories mentioning RPRX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 630,576 | 621,990 | 609,291 | 578,665 | 568,247 | 593,641 | 564,690 | 537,267 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 39,790 | 50,500 | 50,500 | 300,500 | 50,500 | 500.00 | 500.00 | 500.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 563,038 | 388,381 | 427,156 | 209,799 | 534,182 | 361,514 | 735,074 | 269,630 |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (2,201) | (8,169) | (1,575) | (1,543) | (3,062) | (2,189) | (1,654) | 6,000 |
| Pretax Income | 468,256 | 354,913 | 444,211 | 90,635 | 434,433 | 334,351 | 806,358 | 194,377 |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income (Loss) | 294,690 | 213,205 | 288,217 | 30,176 | 239,349 | 208,214 | 543,987 | 102,004 |
| Earnings Per Share (Basic) | 0.67 | 0.50 | 0.67 | 0.07 | 0.55 | 0.46 | 1.22 | 0.23 |
| Earnings Per Share (Diluted) | 0.67 | 0.38 | 0.67 | 0.07 | 0.55 | 0.35 | 1.21 | 0.23 |
| Weighted Average Shares Outstanding (Basic) | 436,790 | 429,801 | 431,887 | 423,514 | 435,480 | 448,185 | 447,628 | 451,020 |
| Weighted Average Shares Outstanding (Diluted) | 556,837 | 564,455 | 559,611 | 562,298 | 578,102 | 594,108 | 592,726 | 596,912 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RPRX
Royalty Pharma plc (NASDAQ: RPRX) is a stock listed on the Nasdaq Stock Market under the ticker symbol RPRX. It last traded at $67.30 (Nov 6, 2026, 9:30 AM ET), down 0.4% on the day. That gives Royalty Pharma a market capitalisation of $36.7B and a price-to-earnings ratio of 45.1.
Over the past 52 weeks RPRX has traded between $37.31 and $69.77.
Revenue for the quarter ended Mar 31, 2026 was $630.6M; net income $294.7M. Revenue was up 11.0% from $568.2M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $630.6M | $294.7M | 46.7% |
| Dec 31, 2025 | $622.0M | $213.2M | 34.3% |
| Sep 30, 2025 | $609.3M | $288.2M | 47.3% |
| Jun 30, 2025 | $578.7M | $30.2M | 5.2% |
From Royalty Pharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…